Recent developments in clinical trials of botulinum neurotoxins
Recent developments in clinical trials of botulinum neurotoxins
复制标题
DOI：
10.1016/j.toxicon.2017.08.014
复制
发表时间：
2018-06-01
期刊：
影响因子：
2.8
通讯作者：
Albanese, Alberto
中科院分区：
文献类型：
--
作者：
Cocco, Antoniangela;Albanese, Alberto
肉毒神经毒素（BoNT）越来越多地用于临床实践中的几个适应症。继多年的发现之后，近年来，新的适应症和新的毒素品牌不断增加。我们在这里回顾了自2014年以来进行的BoNT临床试验，并对其进行了展望。我们还回顾了美国国立卫生研究院登记处（Clinicaltrials.gov）列出的正在进行的试验。本文综述了以下适应症：眼睑痉挛、颈肌张力障碍、痉挛状态、脑瘫、尿失禁、头痛、局部制剂、术后心律失常、瘢痕疙瘩和疤痕。对于这些适应症中的每一个，对最新的试验进行了审查和评论。(C)2017爱思唯尔有限公司版权所有。
Botulinum neurotoxins (BoNTs) are increasingly used in clinical practice for several indications. Following the pioneering years of discoveries, the recent years have witnessed an increase of new indications and new toxin brands.We review here the clinical trials on BoNTs performed since 2014 and put them into perspective. We also review the ongoing trials listed by the National Institutes of Health registry (Clinicaltrials.gov). The following indications are reviewed here: blepharospasm, cervical dystonia, spasticity, cerebral palsy, urinary incontinence, headache, topical formulations, postoperative cardiac arrhythmia, keloids and scars. For each of these indications the latest trials are reviewed and commented. (C) 2017 Elsevier Ltd. All rights reserved.